Could the stock rise by over 2x in value over the next few years? Does this sound a bit ridiculous? Consider this – Pfizer stock was trading at levels of $54 per share just about three years ago.

Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s ...

Sept 23 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's ...

WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo Nordisk’s Ozempic and Wegovy if the company lowers the prices of ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

The most recent trading session ended with Novo Nordisk (NVO) standing at $118.01, reflecting a -0.89% shift from the previouse trading day's closing. This move was narrower than the S&P 500's ...

Sept 26 (Reuters) - German drug and development company Evotec (EVTG.DE), opens new tab has entered into a technology development partnership with Novo Nordisk (NOVOb.CO), opens new tab to support ...

(Bloomberg) -- The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam. Novo shares fell as much as 4.6% to a seven-month low on Friday after a JPMorgan ...

No significant news for NVO in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent ...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...